ChipDX identifies gene expression signature in early-stage breast tumors

[News]

ChipDX LLC, a New York-based molecular diagnostics and personalized medicine research company, has discovered a gene expression signature present in the cells of early-stage breast tumors that indicates the chance of the tumor recurring within 10 years.

More... (http://www.news-medical.net/news/20110504/ChipDX-identifies-gene-expression-signature-in-early-stage-breast-tumors.aspx)